Editas (EDIT), IDT Announce Publication in Nature Communications of Research Data Supporting Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Potential of
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
Go back to Editas (EDIT), IDT Announce Publication in Nature Communications of Research Data Supporting Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Potential of
July 29, 2021 9:00 AM EDT
CAMBRIDGE, Mass. and CORALVILLE, Iowa, July 29, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Integrated DNA Technologies, Inc. (IDT), a leading comprehensive genomics research solutions provider, today announced the publication of research data demonstrating the advantages of Alt-R A.s. Cas12a (Cpf1) Ultra, an engineered AsCas12a nuclease variant, as a tool to eventually enable the development of gene-edited cell medicines. The findings were published in the journal... More